Market Research Report
Global Autoimmune Treatment Market - 2021-2028
|Global Autoimmune Treatment Market - 2021-2028|
Published: September 27, 2021
Content info: 180 Pages
Delivery time: 2 business days
The global autoimmune treatment market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
An autoimmune disorder is the disorder which occurs when the body's immune system is unable to differentiate between own cells and foreign cells due to which body mistakenly attacks normal cells. The symptoms of this disorder include abdominal pain, recurring fever, swollen glands, fatigue, and joint pain, swelling and skin problems.
The global autoimmune treatment market growth is driven by the rise prevalence of autoimmune disease coupled with growing patient awareness levels accounted for the major driver of this market.
The major factor attributing to the growth of the autoimmune treatment market is surge in prevalence of autoimmune diseases. According to NIH (National Institutes of Health) up to 23.5 million Americans have an autoimmune disease and its prevalance is increasing. Scientists have identified 80-100 various autoimmune diseases and assume at least 40 other diseases of having an autoimmune basis. The other factors that play a major role in taking the autoimmune treatment market to the next level are increasing investments in research and development of drugs for autoimmune diseases, technological advancements in diagnosis and awareness of the therapy. Rising government initiatives for regulating these diseases is also helping the growth of the market.
Growing initiatives by the government and pharmaceutical companies to enhance the R&D initiatives to develop new drugs and therapies is expected to drive the market growth. The tremendous technological advancements in the field of autoimmune disorder in the last decade. For instance, phospho-specific flow cytometry technology enables the simultaneous and high-throughput examination of several phosphoepitopes within multiple cell populations, such as distinct immune compartments in the spleen or blood. This approach can facilitate a broad range of novel studies aimed at deciphering intracellular signaling events within heterogeneous populations of primary cells. These factors are driving the market growth in the forecast period.
However, higher costs of the therapeutics and low medical insurance coverage are constraining the market growth.
About 23.5 million Americans live with an autoimmune disease, which gives a cause to concern. Immunosuppression may increase the risk of developing COVID-19 or having a more severe case. Researchers have now found that people with rare autoimmune diseases are at a greater risk of dying at a younger age amid the Covid-19 pandemic. The results also showed that the risk of dying during Covid-19 for people with these conditions increased from age 35.
For many with autoimmune disease, immune modulating or immune suppressing medications are used to help balance an overactive or dysregulated immune system. These medications such as TNF inhibitors like Etanercept, Infliximab or Adalimumab and even steroids such as Prednisone can make individuals more susceptible to infectious diseases caused by bacteria and viruses. Besides being more susceptible to infections, individuals on immunosuppressant medications who become infected may have a more serious illness course than someone not on such a medication during the pendamic. This factor drives the growth of the market in the forecast period.
The rheumatic disease segment is expected to dominate the market owing to the rising cases of diseases. Rheumatic diseases are described by swelling that affects the connecting structures of the body, mostly the joints, sometimes the tendons, ligaments, bones, and muscles.
The therapeutics for rheumatoid disease holds the significant share and expected to remain assertive during the forecast period, due to the rising geriatric population, increasing number of pipeline drugs and the increasing cases of arthritis, fibromyalgia, systemic lupus erythematosus, gout and others, and varied range and availability of progressive therapeutics for the treatment of these diseases.
In 2018, according to RheumatoidArthritis.org, around 1.3 million Americans were affected by Rheumatoid arthritis, and the number is increasing every year, which is a driving factor for the autoimmune treatment market. The economic and social burden of these diseases is huge, without improper approaches to management and control of these diseases, the impact is expected to increase as the population grows. The increasing aging population and certain occupations which lead to injury and overuse of joints are increasing the prevalence of rheumatic disorders. The Centres for Disease Control and Prevention announced data estimating that 54.4 million U.S. adults suffer from arthritis equating to about 25% of the population. Ongoing research on new biologic therapies is anticipated to market growth.
The hospital pharmacy held the largest share in the autoimmune treatment market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
North America region holds the largest market share global autoimmune treatment market
North America region is dominating the global autoimmune treatment market accounted for the largest market share in 2020. This is due to factors such as the rising incidence and prevalence of autoimmune diseases such as arthritis, lupus, multiple sclerosis, in the country. In the North America region, the United States holds the largest market share due to growing personal expenditure on healthcare. The healthcare commerce in the province is developing at a quick stride, resulting in the progress of the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth.
The autoimmune treatment market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Amgen, Johnson & Johnson, Eli Lilly & Co., Pfizer, Roche, Astrazeneca Plc, Bristol-Myers Squibb Co. GlaxoSmithKline Plc, and Lupin Limited among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the autoimmune treatment market globally.
The global autoimmune treatment market report would provide an access to an approximately 45+ market data table, 40+ figures and 180 pages.
LIST NOT EXHAUSTIVE